Late Relapse Is Rare in Testicular Cancer
Data suggest that 0.5% of patients with clinical stage I testicular cancer experience relapse after 10 years.
Data suggest that 0.5% of patients with clinical stage I testicular cancer experience relapse after 10 years.
Modifiable adverse health outcomes affect overall mortality and cancer mortality in testicular cancer survivors.
Certain treatments were associated with an increased risk of death unrelated to testicular cancer.
Guideline-directed care resulted in equivalent outcomes independent of hospital setting.
A subset of testicular cancer survivors experience persistent, treatment-related, long-term adverse health outcomes that affect their ability to work.
Malignant recurrence rate was 1.3 percent at two years for one-cycle BE500P in high-risk early-stage disease.
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
TP53 and MDM2 alterations are associated with resistance to cisplatin and inferior progression-free survival among patients with metastatic germ cell tumors.
A study of twins with 22 980 individuals suggested that the familial risk for testicular cancer may be dramatically underestimated.